

### Indonesia tourism

Market outlook

### Jonathan Mardjuki

jonathan.mardjuki@clsa.com +62 21 5088 7815

### Wirandi Ng

+62 21 5088 7854

9 December 2022

### Indonesia

### **Tourism**

Panorama	PANR IJ
Rec	Non-rated
Market cap	USD30mn
3M ADV	USD166k
Price	Rp402
Target	N/A
Up/downside	N/A

Multi Bintang	MLBI IJ
Rec	Non-rated
Market cap	USD1.2bn
3M ADV	USD36k
Price	Rp9,150
Target	N/A
Un/downside	N/A

Blue Bird	BIRD IJ
Rec	Non-rated
Market cap	USD245mn
3M ADV	USD446k
Price	Rp1,545
Target	N/A
Up/downside	N/A

Pakuwon	PWON IJ
Rec	BUY
Market cap	USD1.4bn
3M ADV	USD1mn
Price	Rp476
Target	Rp620
Up/downside	+30%

### Air Asia Indonesia CMPP IJ Rec Non-rated Market cap USD125mn 3M ADV USD31k Price Rp176 Target N/A Up/downside N/A

### **Come to Indonesia**

Tourism sector, anecdotes from travel agency, colour on airlines business December is always a good month to visit Indonesia, with the country's all yearlong tropical season. The tourism sector is back in the spotlight again, with international tourist arrivals improving in past few months although still below pre-pandemic levels. Anecdotes from travel agency Panorama are interesting, with recovery in both inbound and outbound activities, aligned with normalization of airlines industry driven by the low cost carriers such as Citilink. The ongoing revival of tourism industry would benefit certain sectors such as airlines, travel agency, beer producers, hotel, taxi operators, etc.

### Indonesia tourism - 'back in the spotlight'

- Our recent trip to 'Kota Tua' or 'Old Town' in North Jakarta is an interesting example, where several revitalizations have been done to make it friendlier for tourists/visitors.
- □ Number of foreign tourist arrivals have continued to recover in past few months and the overall tourism sector in Indonesia seems to be back in the spotlight.
- □ October had the highest number of tourists at 446k, although still 52% of pre-pandemic levels. Tourist arrivals to Bali have improved significantly, which is also reflected in beer sales of Multi Bintang in the Island; Rp400bn in 9M22, +110% YoY.

### 'Revenge travel' by Panorama (PANR)

- □ Past two quarters have been a relief for travel agencies such as Panorama. Its 3Q22 revenue is back to pre-Covid, due to recovery in outbound and inbound business.
- Outbound activity has kick-started, with Turkey, USA and Europe being the earliest to open for international visits, and more recently Asian countries such as South Korea.
- □ Seizing the opportunity, PANR has initiated a smart strategy to grab 'travel pent-up for the Muslim population in the country by launching creative packages such as combination of 'Umrah' and tour to Turkey, with a price of Rp39.9mn per person.

### Inbound activity - let's enjoy what Indonesia can offer

- □ Travel agencies continue to focus on their inbound business. For instance, PANR has been actively participating in travel fair since the beginning of the year by promoting a number of tourist destinations from Toba Lake to Belitung in Sumatra (chart below).
- □ Demand for inbound (domestic travel) activities have picked up since easing of covid restrictions by the government, especially in Bali since July.
- ☐ The inbound recovery is also evident from rebound in Indonesia airlines revenue, +75% YoY in 2021 after -67%, led by low cost carrier, Citilink.

### **Come visit Indonesia**

- ☐ The worst seems to be over for Indonesia's tourism industry and the government optimistically hopes for a +130% YoY rebound in foreign arrivals in 2022.
- ☐ The revival of tourism benefits certain sectors and their respective market leaders, from airlines (Garuda Indonesia & Air Asia Indonesia), travel agency (Panorama & Bayu Buana), beer producer (Multi Bintang) and hotel operator (Pakuwon & Surya Semesta).



www.clsa.com



## Click to rate this research

### Come to Indonesia

Come visit Jakarta

December is always a good month to visit Indonesia, with the country's all-yearlong tropical season that offers warm weather despite high humidity. Jakarta is definitely one nice destination, capital city that has seen many improvements in efforts to attract tourism after the two rough pandemic years. Our recent visit to tourism spot, 'Kota Tua' or 'Old Town' (figure 1) in North of Jakarta is an interesting example, where several revitalizations can be seen especially the pedestrian roads to make it friendlier for visitors. It was rather quiet during our visit, since it was afternoon on weekdays. The area is packed with a lot of parked vehicles and motorcycles during the weekend. But, it was also an enjoyable experience to learn a little bit about financial industry from Bank Indonesia or Central Bank Museum (figure 2).

Solid

Figure 1

Jakarta's tourist attraction, Kota Tua



### Bank Indonesia (Central Bank) Museum



Source: CLSA

Kota Tua in North Jakarta could be one option for tourists It is a very classic and historical Museum, which has 'lived' since 1828 as first headquarters of 'Netherlands Indies Gulden', Central Bank of Dutch East Indies, before it was finally nationalized as Bank Indonesia in 1953. The heritage building was opened to public in 2009 and offers quite an interesting view from the history of formation of Indonesian's Central Bank (figure 3) to Indonesia's currency design from time to time (figure 4). This memorable short trip also opened our mind to look at how the Indonesian tourism industry has recovered from the bottom, not only in Jakarta but also other important destinations like Bali.

Figure 3

Source: CLSA

History of Indonesia's Central Bank



Source: CLSA

Figure 4

### Inside Bank Indonesia Museum



Source: CLSA

Find CLSA research on Bloomberg, Thomson Reuters, FactSet and CapitalIQ - and profit from our evalu@tor proprietary database at clsa.com




International tourist arrival numbers have been encouraging for past few months

### Indonesia tourism - back in the spotlight

'Back in the spotlight' seems to be the right word to describe the tourism industry in Indonesia, although it will still take a while for the sector to return back to the level it was before 2020 (figure 5). The worse seems to be now behind us, with foreign tourist arrivals starting to pick up since Mar-22. October had the highest arrivals, with 446k of foreigners, about 52% of 856k in Oct-19. The tourist arrival recovery is seen across all the regions (figure 6)- from ASEAN, Asia, Europe to America. The first two improved the most, supported by countries like Malaysia and Singapore. Malaysia accounted for the most foreign visitors (3mn) in Indonesia in 2019, followed by Singapore and Australia.

Figure 5





Source: CLSA, Government


Source: CLSA, Government

## mention of the control of the contro


### Figure 7

### Who doesn't love Bali?

There are couple of destinations in Indonesia that we recommend to visit and adding new tourism spot seems to be always key priority by government. One of them is Mandalika, which we have highlighted in our 'The next Bali' report before. But recovery of Bali is the government's current main objective, as the Island is always an important source of tourism revenue. It is a positive sign that the number of tourist arrivals to Bali is increasing, reaching 305k by October (figure 7), 54% of pre-pandemic levels. Therefore, it is also not a coincidence that beer companies such as Multi Bintang (MBLI) registered increase in their beer sales in Bali (figure 8).



Source: CLSA, Government



Source: CLSA, MLBI



Travel agency Panorama has posted strong performance in the past two quarters

### 'Revenge travel' by Panorama (PANR)

Airlines industry is always the direct beneficiary of the recovery in tourism sector, with improvement in flight frequency across the globe. But our recent discussion with one of the largest travel agency firms, Panorama (Not rated) also provides colourful anecdotes on how the company has seen 'travel pent-up demand' or 'revenge travel' for both inbound (travelling in Indonesia) and outbound (travelling abroad) businesses. Panorama's financial performance (figure 9 and 10) is a strong evidence with encouraging revenue and profitability in past two quarters, as countries around the globe starting to ease border restrictions.

Figure 9




Figure 10

Panorama (PANR) quarterly net profit trend

20 (Robin)
10 Panorama quarterly profit trend
10 (10)
(20)
(30)
(40)
(50)
(60)
(70)
(80)

1100

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700

2700


Source: CLSA, PANR

Both inbound and outbound are recovering quite strongly

Source: CLSA, PANR

In 2019 (pre-covid), tour and travel represented 90% of Panorama's total revenue; outbound was the key driver with 75% of tour and travel revenue, and the rest 25% from inbound. Both segments have only began to recover in 2Q this year (figure 12), but the 'one-off' outbound sales in 3Q20 was interesting, which only happened one quarter after the first lockdown around the globe. It all started with Turkey being one of the first country to open border for international tourists in the middle of 2020. Panorama saw surging demand for tour to Turkey in 3Q.

Figure 11



Source: CLSA, PANR

Source: CLSA, PANR



Outbound activity is gaining traction since border reopening

### Outbound - You can travel around the globe...

It feels like a relief to realize that travelling is now feasible, one of things that at one point we thought it would never be possible again because of the pandemic. Indonesians tend to love travel abroad, especially since the past 10-15 years where tourism business is growing rapidly. Panorama's outbound revenue has grown from Rp260bn in 2010 to Rp1.3tn in 2019. It was Rp660bn in 2020, Rp66bn in 2021 and has rebounded to Rp650bn in 9M22. Tourist re-opening has largely kicked-in since late last year, from Europe and USA in 2021 and more to Asia countries in 2022 such as South Korea in middle of the year and Japan as the latest. Anecdotally, one reason of Panorama's high demand for USA last year was vaccination package, where everyone was trying to get jabbed faster for health and safety purpose.

Panorama has been focusing to create innovative travel package

The company has been opportunistic and quick to monetize the re-opening opportunity by introducing several catchy and attractive travel packages like tour to South Korea for 5-6 days with price per person starting from Rp15.4mn (figure 14). Similarly, Panorama has also been trying to grab the travel pent-up from the large Muslim population in the country, with the launch of creative packages such as combination of 'Umrah' (or pilgrimage to Mecca in Saudi Arabia) and tour to Turkey, a country close to it (figure 13). The whole trip lasts for 13 days, scheduled for 11 to 23 January 2023, flying with Turkish Airlines and price tag of Rp39.9mn per person. Management has seen growing appetite for this type of tour service in past six months and it has even formed a special division for Muslim tour product. More importantly, the business is also more profitable as Muslim tourists in general do not seem concerned about the price as long as the travel agency could provide a good service. Service here means service that is related to the religion, such as ability to consistently provide halal food/product throughout the trip.

Figure 13

Source:PANR

Panorama's popular Muslim tour package



Figure 14

Panorama's growing tour package to South Korea



Source: PANR

Global number of tourists have come closer and closer to the pre-Pandemic level With all of these positive signs, management is positive heading into 2023 with the expectation that the whole tourism industry is stepping into a much better position. This can also be seen through the robust recovery trend from the number of tourists globally (figure 15), where there already were 705mn of tourists travelling around the world in first nine months of 2022, which is already 63% of normal (figure 16), versus 31% in 2021 and 29% in 2020. Panorama's overall inbound and outbound revenues are still 27% and 72% of pre-Covid in 3Q22. Per management, these figures could improve going ahead as pent-up demand is higher than management's expectation since the reopening, but the overall capacity (i.e. flight frequency,



Panorama still sees high airlines ticket sales

Targeting corporate segment is another strategy by travel agencies

hotel's readiness, etc) is still lagging behind. Based on our observation, round flight trip from Jakarta to Seoul is priced around Rp10mn per person for second & third week of December before the high season in last week of the month. This is roughly 20-25% higher than pre-pandemic levels. Another example would be the Rp10-15mn round trip ticket price from Jakarta to Singapore during middle of the year, versus Rp2-3mn normally, although the price has consistently dropped to Rp2-4mn at the moment. The unstable supply and demand has even produced an unusual outcome or 'phenomena', where Panorama management once observed that ticket price for business class from Jakarta to London was cheaper than the economy class.

Targeting corporate segment is another strategy adopted by travel agencies such as Panorama, with a lot of demand for corporate outing after working from home for two years. Per PANR, one giant consulting firm based in Jakarta has booked overseas travelling plan for more than 3,000 employees.

Figure 15





Figure 16



Source: CLSA, UNWTO Source: CLSA, UNWTO



IR dooneanina has peeks foorflooffloor, in boorun Batiotorie titelis December

### Inbound - Or let's enjoy what Indonesia can offer...

We have highlighted the potential of domestic tourism market through a series of reports 'Wonderful Indonesia', 'Keep calm and travel more', 'Welcoming 2019' to 'Recovery starts at home'. Travel agency companies in the domestic space have been very innovative off late. For instance, PANR has been actively participating in the travel fair events since the beginning of the year. One of them is the Garuda Indonesia Travel Fair (figure 18) that was held in Indonesia Convention Exhibition (ICE) in BSD City from 28 to 30 October. It offers i.e. one way ticket from Jakarta to Denpasar Bali from Rp888k, which is considered attractive. There are couple of 'gimmicks' such as cash back up to Rp3mn, 12 months instalment with 0% interest or free travel youcher & luggage.

Despite inbound activity still far below normal level, the turning point for this segment was when the government finally eased a number of restrictions since late 2021/early 2022, from resumption of visa on arrival at the airport (this was prohibited for two years since Feb/Mar-20, except for 'Dinas' or Official's travel) to doing away with PCR testing for visitors. Panorama saw more demand for inbound market since July especially to Bali Island. From the government data (figure 7), foreign travellers to Bali began to appear since Feb this year from 1.3k. Aside from Bali, there are couple of domestic trip packages from Panorama (figure 17), to support other destinations from Toba Lake, Belitung, Banda Aceh in Sumatra to Moratai Island in Maluku. Management continues to see better demand in the last



three months and the company hopes to welcome 3,000 inbound tourists in December (40% during normal year in December). Panorama used to accommodate its agency service for 30k inbound travellers before 2020.

Figure 17

# Panorama's catchy domestic tour package | Company | Com

Figure 18

### Panorama's participation in Garuda Indonesia Travel Fair



Source: PANR

Source: PANR

Low cost carrier, Citilink has been gaining market share during the Pandemic

### A glance at Indonesia's airlines industry

Being amongst the hardest hit by the Pandemic, airlines industry has slowly bounced back over the past two years. Sales of airlines in Indonesia dropped heavily by -67% YoY in 2020 to Rp32.3tn and saw a strong rebound of +75% YoY in 2021. Euromonitor projects another +47% YoY uptick in 2022 and only expects it to return to 2019 levels by 2024/2025 (figure 19). The interesting trend is the change in competition landscape (figure 20). Although Garuda Indonesia (GIAA) remains the market leader with 21.5% share in 2022, its low cost carrier Citilink has seen meaningful gain in market share during the pandemic, mainly due to change in consumer behaviour towards affordable airlines, which we think is partly caused by expensive flight price on the back of lower capacity.

Figure 19




Figure 20



Source: CLSA, Euromonitor

Traveloka remains to hold the largest market share for travel intermediaries

This is also reflected in number of monthly passenger carried by three airlines in Indonesia (figure 21); both low cost carriers Air Asia Indonesia (CMPP) and Citilink and Garuda Indonesia as full service carriers. Both Air Asia Indonesia and Citilink




have been performing better since the Pandemic started. Citilink has been carrying more passengers than Garuda Indonesia, which is a new trend where Garuda always had higher passengers before 2020. Market share for travel intermediaries (figure 22) is the other interesting finding with online travel and ticketing firm, Traveloka continues its dominance in the business, despite seeing a bit of contraction in 2020. Traveloka holds 41.5% of market share in 2022, followed by Tiket.com of 17%, Dwidaya Tour 4.1% and Panorama 2.2%.

Figure 21



Figure 2



Source: CLSA, Euromonitor

The government targets

fast recovery for

Indonesia's tourism

### Come visit Indonesia

The pandemic was frustrating for the Indonesian government in its ambitious mission to boost the tourism sector. Indonesia once had a peak of 16.1mn of international tourists in 2019 (figure 23), with years of efforts to grow the figure from only 9.4mn in 2014. It dropped by -75% YoY and -61% YoY in both 2020 and 2021 and the Tourism Ministry hopes for a 130% YoY rebound to 3.6mn in 2022 and double again to reach 7.4mn next year. Euromonitor has provided detailed information on the inbound tourist spending in Indonesia (figure 24), with retail shopping the highest in 2022 at Rp37tn, mobility, duty free shopping, Spas, theme parks, museum, food and dining to medical tourism.

Figure 23





Figure 24



Source: CLSA, Euromonitor




Airlines, travel agency, beer producer, taxi operators, and hotel operators are beneficiaries of tourism recovery

Sales to pre-Covid look encouraging across these sectors

### The beneficiaries


There are a lot of sectors and companies that will benefit from the tourism recovery theme. We list beneficiary sectors and the top 1 or 2 companies based on market capitalisation- Airlines operators; Garuda Indonesia (GIAA USD626mn market cap) and Air Asia Indonesia (CMPP, USD125mn market cap), travel agency; Panorama (PANR, USD30mn market cap) and Bayu Buana (BAYU, USD22mn market cap), beer producer (MLBI, USD1.2bn market cap), taxi operator; Blue Bird (BIRD, USD245mn market cap), hotel operators; Pakuwon (PWON, USD1.4bn market cap) and Surya Semesta (SSIA, USD88mn market cap). Note that both Pakuwon and Surya Semesta are originally property/industrial estate developers. Hotel is only 5-10% of their business. Current sales as a percentage of pre-covid levels look encouraging. For instance, improvement can be seen across the aforesaid companies since 2020, 2021 and 9M22 (figure 25). Pakuwon leads the faster recovery with its hotel revenue already 60% above 9M19, in part thanks to hotel expansions and acquisitions. Sales of beer producer Multi Bintang has reached 86% of pre-covid, with sharp recovery in both Bali and some other regions. Better mobility and reopening has helped improve revenue for the largest taxi operator Blue Bird, together with travel agency and airlines.

Figure 25




Source: CLSA, Companies. Note: This report replaces a previous version and corrects the mention of Pakuwon in the figure above.

Figure 26




Source: CLSA, Companies. Note: This report replaces a previous version and corrects the mention of Pakuwon in the figure above.

Figure 27



Source: CLSA, UNWTO


Figure 2



Source: CLSA, UNWTO



### Appendix - Wonderful Indonesia



Source: Tourism Ministry



Source: Tourism Ministry

Figure 31



Source: Tourism Ministry



Source: Tourism Ministry




Figure 33



Source: Tourism Ministry

Figure 34



Source: Tourism Ministry



### Research subscriptions

To change your report distribution requirements, please contact your CLSA sales representative or email us at cib@clsa.com. You can also fine-tune your Research Alert email preferences at https://www.clsa.com/member/tools/email\_alert/.

### Companies mentioned

Air Asia Indonesia CMPP (N-R)

Air France KLM (N-R)

Batik Air (N-R)

Bayu Buana (N-R)

Blue Bird (N-R)

Booking (N-R)

Cathay Pacific (293 HK - HK\$8.50 - BUY)

Citilink (N-R)

Dwidaya Tour (N-R)

**Emirates Airlines (N-R)** 

Etihad Airways (N-R)

Garuda Indonesia (N-R)

Golden Rama (N-R)

Lion Air (N-R)

Multi Bintang (N-R)

NAM Air (N-R)

Pakuwon (PWON IJ - RP476 - BUY)

Panorama Sentra (N-R)

PT Sriwijaya (N-R)

Qatar Airways (N-R)

Saudia Airways (N-R)

Singapore Airlines (SIA SP - S\$5.56 - U-PF)

Smailing Tour (N-R)

Surya Semesta (SSIA IJ - RP290 - U-PF)

Tiket.com (N-R)

Trans Lifestyle (N-R)

Traveloka (N-R)

Wings Air (N-R)

Wisata Dewa (N-R)

### Analyst certification

The analyst(s) of this report hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this research report.

### Important disclosures

Note: This report replaces a previous version and corrects the mention of Pakuwon in Figures 25 and 26.















Date	Rec	Target	Date	Rec	Target
07 Nov 2022	U-PF	5.50	12 Nov 2021	SELL	3.90
29 Jul 2022	O-PF	6.20	30 Jul 2021	SELL	3.80
19 May 2022	O-PF	6.10	03 May 2021	SELL	4.20
27 Feb 2022	O-PF	5.60			


Source: CLSA



Date	Rec	Target	Date	Rec	Target
15 Sep 2022	BUY	620.00	11 Nov 2020	O-PF	520.00
07 Jul 2022	BUY	580.00	19 Oct 2020	U-PF	410.00
19 Oct 2021	O-PF	585.00	04 Aug 2020	U-PF	413.00
14 Jul 2021	O-PF	505.00	29 Jun 2020	U-PF	452.68
17 Feb 2021	O-PF	605.00	15 Apr 2020	U-PF	415.59
10 Jan 2021	O-PF	580.00	27 Mar 2020	U-PF	305.60
10 Dec 2020	O-PF	550.00	10 Dec 2019	U-PF	635.00


Source: CLSA





Date	Rec	Target	Date	Rec	Target
10 Aug 2022	BUY	10.40	13 Nov 2020	BUY	8.00
25 Jun 2022	BUY	9.50	21 Oct 2020	O-PF	6.60
23 Apr 2022	BUY	9.40	15 Oct 2020	O-PF	6.20
24 Jan 2022	O-PF	7.30	12 Aug 2020	SELL	5.30
18 Jan 2022	O-PF	7.20	24 Jun 2020	SELL	6.30*
13 Dec 2021	O-PF	7.30	09 Jun 2020	SELL	6.53*
11 Aug 2021	O-PF	7.10	23 Mar 2020	U-PF	7.67*
24 Feb 2021	O-PF	8.30	11 Mar 2020	BUY	10.71*
28 Jan 2021	BUY	8.40	06 Feb 2020	BUY	10.98*
20 Nov 2020	BUY	8.80			

Source: CLSA; \* Adjusted for corporate action



Date	Rec	Target	Date	Rec	Target
09 May 2022	U-PF	394.00	02 Aug 2020	U-PF	389.45
19 Nov 2020	O-PF	623.00	21 Apr 2020	U-PF	325.00
07 Oct 2020	U-PF	469.00	18 Dec 2019	BUY	875.00

Source: CLSA

CLSA ("CLSA") in this report refers to CLSA Limited, CLSA Americas, LLC, CLSA Australia Pty Ltd, CLSA India Private Limited, PT CLSA Sekuritas Indonesia, CLSA Securities Japan Co., Ltd., CLSA Securities Korea Ltd., CLSA Securities Malaysia Sdn. Bhd., CLSA Philippines, Inc, CLSA Singapore Pte Ltd, CLSA Securities (Thailand) Limited, CLSA

(UK), CLSA Europe B.V. and/or their respective affiliates. CLST ("CLST") in this report refers to CL Securities Taiwan Co., Ltd.

The policies of CLSA and CLST are to only publish research that is impartial, independent, clear, fair, and not misleading. Regulations or market practice of some jurisdictions/markets prescribe certain



disclosures to be made for certain actual, potential or perceived conflicts of interests relating to a research report as below. This research disclosure should be read in conjunction with the research disclaimer as set out hereof and at www.clsa.com/disclaimer.html, the Terms and Conditions of Use as set out at https://www.clsa.com/terms-and-conditions-of-use/ and the applicable regulation of the concerned market where the analyst is stationed and hence subject to. Investors are strongly encouraged to review this disclaimer before investing.

Neither analysts nor their household members or associates may have a financial interest in, or be an officer, director or advisory board member of companies covered by the analyst unless disclosed herein. In circumstances where an analyst has a pre-existing holding in any securities under coverage, those holdings are grandfathered and the analyst is prohibited from trading such securities.

The analysts included herein hereby confirm that they have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts attest that they were not in possession of any material, nonpublic information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. (For full disclosure of interest for all companies covered by CLSA in this report, please refer to http://www.clsa.com/member/research\_disclosures/ for details.)

As analyst(s) of this report, I/we hereby certify that the views expressed in this research report accurately reflect my/our own personal views about the securities and/or the issuers and that no part of my/our compensation was, is, or will be directly or indirectly related to the specific recommendation or views contained in this report or to any investment banking relationship with the subject company covered in this report (for the past one year) or otherwise any other relationship with such company which leads to receipt of fees from the company except in ordinary course of business of the company. The analyst/s also state/s and confirm/s that he/she/they has/have not been placed under any undue influence, intervention or pressure by any person/s in compiling this research report. In addition, the analysts included herein attest that they were not in possession of any material, non-public information regarding the subject company that has securities listed in the relevant jurisdiction(s) at the time of publication of this report. The analysts further confirm that none of the information used in this report was received from CLSA's Corporate Finance department or CLSA's and/or CLST's Sales and Trading business. Save from the disclosure below (if any), the analyst(s) is/are not aware of any material conflict

For the companies under research coverage, CLSA and/or CLST expect(s) to receive or intend(s) to seek compensation for investment banking services from Cathay Pacific Airways Ltd in the next three months.

Key to CLSA/CLST investment rankings: BUY: Total stock return (including dividends) expected to exceed 20%; O-PF (aka ACCUMULATE): Total expected return below 20% but exceeding market return; U-PF (aka REDUCE): Total expected return positive but below market return; SELL: Total return expected to be negative. For relative performance, we benchmark the 12-month total forecast return (including dividends) for the stock against the 12-month forecast return (including dividends) for the market on which the stock trades.

"High Conviction" Ideas are not necessarily stocks with the most upside/downside, but those where the Research Head/Strategist believes there is the highest likelihood of positive/negative returns. The list for each market is monitored weekly.

Overall rating distribution for CLSA (exclude CLST) only Universe: Overall rating distribution: BUY / Outperform - CLSA: 76.39%, Underperform / SELL - CLSA: 23.61%, Restricted - CLSA: 0.09%; Data as of 3 Oct 2022. Investment banking clients as a % of rating category: BUY / Outperform - CLSA: 13.3%, Underperform / SELL - CLSA: 2.75%; Restricted - CLSA: 0.09%. Data for 12-month period ending 3 Oct 2022

Overall rating distribution for CLST only Universe: Overall rating distribution: BUY / Outperform - CLST: 67.86%, Underperform / SELL - CLST: 32.14%, Restricted - CLST: 0.00%. Data as of 3 Oct 2022. Investment banking clients as a % of rating category: BUY / Outperform - CLST: 0.00%, Underperform / SELL - CLST: 0.00%,

Restricted - CLST: 0.00%. Data for 12-month period ending 3 Oct 2022.

There are no numbers for Hold/Neutral as CLSA/CLST do not have such investment rankings. For a history of the recommendation, price targets and disclosure information for companies mentioned in this report please write to: CLSA Group Compliance, 18/F, One Pacific Place, 88 Queensway, Hong Kong and/or; CLST Compliance (27/F, 95, Section 2 Dun Hua South Road, Taipei 10682, Taiwan, telephone (886) 2 2326 8188). EVA® is a registered trademark of Stern, Stewart & Co. "CL" in charts and tables stands for CLSA estimates, "CT" stands for CLST estimates, "CRR" stands for CRR Research estimates and "CS" for Citic Securities estimates unless otherwise noted in the source.

Charts and tables sourced to CLSA in this report may include data extracted from CLSA's automated databases, which derive their original data from a range of sources. These can include: companies; analyst estimates/calculations; local exchanges and/or third-party data or market pricing providers such as Bloomberg, FactSet or IBES. Additional information on data sources for specific charts or tables can be obtained by contacting the publishing analysts.

This report is subject to and incorporates the terms and conditions website set out on the www.clsa.com (https://www.clsa.com/disclaimer.html and https://www.clsa.com/terms -and-conditions-of use/) and the references to "publication/communication" or "Publications" thereof shall include this report. Neither this report nor any portion hereof may be reprinted, sold, resold, copied, reproduced, distributed, redistributed, published, republished, displayed, posted transmitted in any form or media or by any means without the written consent of CLSA and/or CLST. CLSA and/or CLST has/have produced this report for private circulation to professional, institutional and/or wholesale clients only, and may not be distributed to retail investors. The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject CLSA and/or CLST to any additional registration or licensing requirement within such jurisdiction. The information and statistical data (for private or public companies) herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and CLSA and/or CLST makes no representation or warranty as to its fairness, adequacy, accuracy, completeness or correctness. The replication of any third party views in this report should not be treated necessarily as an indication that CLSA and/or CLST agrees with or concurs with such views. None of CLSA and/or CLST, its affiliates and their respective directors, officers, employees, advisers and representatives makes any representation or warranty, express or implied, as to and no reliance should be placed on, the fairness, accuracy, completeness or correctness of such data or information contained herein or any statement made in this report. Any opinions or estimates herein reflect the judgment of CLSA and/or CLST at the date of this report and are subject to change at any time without notice. Where any part of the information, opinions or estimates contained herein reflects the views and opinions of a sales person or a non-analyst, such views and opinions may not correspond to the published view of CLSA and/or CLST. Any price target given in the report may be projected from one or more valuation models and hence any price target may be subject to the inherent risk of the selected model as well as other external risk factors. Where the publication does not contain ratings, the material should not be construed as research but is offered as factual commentary. It is not intended to, nor should it be used to form an investment opinion about the non-rated companies.

This report is for information purposes only and it does not constitute or contain, and should not be considered as an offer or invitation to sell, or any solicitation or invitation of any offer to subscribe for or purchase any securities in any jurisdiction and recipient of this report must make its own independent decisions regarding any securities or financial instruments mentioned herein. This is not intended to provide professional, investment or any other type of advice or recommendation and does not take into account the particular investment objectives, financial situation or needs of individual recipients. Before acting on any information in this report, you should consider whether it is suitable for your particular circumstances and, if appropriate, seek professional advice, including



legal or tax advice. Investments involve risks, and investors should exercise prudence and their own judgment in making their investment decisions. The value of any investment or income may go down as well as up, and investors may not get back the full (or any) amount invested. Investments that are denominated in foreign currencies may fluctuate in value as a result of exposure to movements of exchange rate. Past performance is not necessarily a guide to future performance or liquidity. CLSA and/or CLST do/does not accept any responsibility and cannot be held liable for any person's use of or reliance on the information and opinions contained herein. To the extent permitted by applicable securities laws and regulations, CLSA and/or CLST accept(s) no liability whatsoever for any direct or consequential loss arising from the use of this report or its contents.

To maintain the independence and integrity of our research, our Corporate Finance, Sales Trading, Asset Management and Research business lines are distinct from one another. This means that CLSA's Research department is not part of and does not report to CLSA's Corporate Finance department or CLSA's Sales and Trading business. Accordingly, neither the Corporate Finance department nor the Sales and Trading department supervises or controls the activities of CLSA's research analysts. CLSA's research analysts report to the management of the Research department, who in turn report to CLSA's senior management. CLSA has put in place a number of internal controls designed to manage conflicts of interest that may arise as a result of CLSA engaging in Corporate Finance, Sales and Trading, Asset Management and Research activities. Some examples of these controls include: the use of information barriers and other controls designed to ensure that confidential information is only shared on a "need to know" basis and in compliance with CLSA's Chinese Wall policies and procedures; measures designed to ensure that interactions that may occur among CLSA's Research personnel, Corporate Finance, Asset Management, and Sales and Trading personnel, CLSA's financial product issuers and CLSA's research analysts do not compromise the integrity and independence of CLSA's

Subject to any applicable laws and regulations at any given time, CLSA, CLST, their respective affiliates, officers, directors or employees may have used the information contained herein before publication and may have positions in, or may from time to time purchase or sell or have a material interest in any of the securities mentioned or related securities, or may currently or in future have or have had a business or financial relationship with, or may provide or have provided corporate finance/capital markets and/or other services to, the entities referred to herein, their advisors and/or any other connected parties. As a result, you should be aware that CLSA and/or CLST and/or their respective affiliates, officers, directors or employees may have one or more conflicts of interest. Regulations or market practice of some jurisdictions/markets prescribe certain disclosures to be made for certain actual, potential or perceived conflicts of interests relating to research reports. Details of the disclosable interest can be found in certain reports as required by the relevant rules and regulation and the full details of conflict of interest with companies under coverage are available http://www.clsa.com/member/research\_disclosures/. therein include the position of CLSA and CLST only. Unless specified otherwise, CLSA did not receive any compensation or other benefits from the subject company, covered in this report, or from any third party. If investors have any difficulty accessing this website, please contact webadmin@clsa.com. If you require disclosure information on previous dates, please contact compliance\_hk@clsa.com.

Any disputes related to this report shall be governed by the laws of Hong Kong and to the non-exclusive jurisdiction of the courts of Hong Kong in connection with any suite, action or proceeding arising out of or in connection with this material. In the event any of the provisions in these Terms of Use shall be held to be unenforceable, that provision shall be enforced to the maximum extent permissible to reflect the intention underlying the unenforceable term, and the remainder of these General Disclaimer shall be unimpaired.

This report is distributed for and on behalf of CLSA (for research compiled by non-US and non-Taiwan analyst(s)), CLSA Americas, LLC (for research compiled by US analyst(s)) and/or CLST (for research compiled by Taiwan analyst(s)) in Australia by CLSA Australia Pty Ltd (ABN 53 139 992 331/AFSL License No: 350159); in Hong Kong by CLSA Limited (Incorporated in Hong Kong with limited liability); in

India by CLSA India Private Limited, (Address: 8/F, Dalamal House, Nariman Point, Mumbai 400021. Tel No: +91-22-66505050. Fax No: +91-22-22840271: CIN: U67120MH1994PLC083118; Registration No: INZ000001735 as Stock Broker, INM000010619 as Merchant Banker and INH000001113 as Research Analyst; in Indonesia by PT CLSA Sekuritas Indonesia; in Japan by CLSA Securities Japan Co., Ltd.; in Korea by CLSA Securities Korea Ltd.; in Malaysia by CLSA Securities Malaysia Sdn. Bhd.; in the Philippines by CLSA Philippines Inc (a member of Philippine Stock Exchange and Securities Investors Protection Fund); in Singapore by CLSA Singapore Pte Ltd and solely to persons who qualify as an "Institutional Investor", "Accredited Investor" or "Expert Investor" MCI (P) 042/11/2022; in Thailand by CLSA Securities (Thailand) Limited; in Taiwan by CLST (for reports compiled by Taiwan analyst(s) or CLSA (for non Taiwan stock reports to CLSA clients) and in the European Economic Area ('EEA") by CLSA Europe BV and in the United Kingdom by CLSA (UK).

Hong Kong: This research report is distributed by CLSA Limited. This research report is distributed in Hong Kong only to professional investors (as defined in the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) and any rules promulgated thereunder) and may not be distributed to retail investors. Recipients should contact CLSA Limited, Tel: +852 2600 8888 in respect of any matters arising from, or in connection with, the analysis or report.

Australia: CLSA Australia Pty Ltd ("CAPL") (ABN 53 139 992 331/AFS License No: 350159) is regulated by ASIC and is a Market Participant of ASX Limited and CHI-X. This material is issued and distributed by CAPL in Australia to "wholesale clients" only. This material does not take into account the specific investment objectives, financial situation or particular needs of the recipient. The recipient of this material must not distribute it to any third party without the prior written consent of CAPL. For the purposes of this paragraph the term "wholesale client" has the meaning given in section 761G of the Corporations Act 2001. CAPL's research coverage universe spans listed securities across the ASX All Ordinaries index, securities listed on offshore markets, unlisted issuers and investment products which Research management deem to be relevant to the investor base from time to time. CAPL seeks to cover companies of relevance to its domestic and international investor base across a variety of sectors.

India: CLSA India Private Limited, incorporated in November 1994 provides equity brokerage services (SEBI Registration No: INZ000001735), research services (SEBI Registration No: INH000001113) and merchant banking services (SEBI Registration No: INH000010619) to global institutional investors, pension funds and corporates. CLSA and its associates may have debt holdings in the subject company. Further, CLSA and its associates, in the past 12 months, may have received compensation for non-investment banking services and/or non-securities related services from the subject company. For further details of "associates" of CLSA India please contact Compliance-India@clsa.com.

Singapore: This report is distributed in Singapore by CLSA Singapore Pte Ltd to institutional investors, accredited investors or expert investors (each as defined under the Financial Advisers Regulations) only. Singapore recipients should contact CLSA Singapore Pte Ltd, 80 Raffles Place, #18-01, UOB Plaza 1, Singapore 048624, Tel: +65 6416 7888, in respect of any matters arising from, or in connection with, the analysis or report. By virtue of your status as an institutional investor, accredited investor or expert investor, CLSA Singapore Pte Ltd is exempted from complying with certain requirements under the Financial Advisers Act (Chapter 110), the Financial Advisers Regulations and the relevant Notices and Guidelines issued thereunder (as disclosed in Part C of the Securities Dealing Services - Singapore Annex of the CLSA terms of business), in respect of any financial advisory services that CLSA Singapore Pte Ltd may provide to you. MCI (P) 042/11/2022

United States of America: Where any section of the research is compiled by US analyst(s), it is distributed by CLSA Americas, LLC. Where any section is compiled by non-US analyst(s), it is distributed into the United States by CLSA (except CLSA Americas, LLC) solely to persons who qualify as "Major US Institutional Investors" as defined in Rule 15a-6 under the Securities and Exchange Act of 1934 and who deal with CLSA Americas, LLC. However, the delivery of this research report to any person in the United States shall not be deemed a



recommendation to effect any transactions in the securities discussed herein or an endorsement of any opinion expressed herein. Any recipient of this research in the United States wishing to effect a transaction in any security mentioned herein should do so by contacting CLSA Americas, LLC.

The United Kingdom: This document is a marketing communication. It has not been prepared in accordance with the legal requirements designed to promote the independence of investment research, and is not subject to any prohibition on dealing ahead of the dissemination of investment research. The document is disseminated in the UK by CLSA (UK) and directed at persons having professional experience in matters relating to investments, as defined in the relevant applicable local regulations. Any investment activity to which it relates is only available to such persons. If you do not have professional experience in matters relating to investments you should

not rely on this document. Where research material is compiled by UK analyst(s), it is produced and disseminated by CLSA (UK). For the purposes of the Financial Conduct Rules in the UK such material is prepared and intended as substantive research material. CLSA (UK) is authorised and regulated by the Financial Conduct Authority.

The European Economic Area ('EEA"): research is distributed by CLSA Europe BV, authorised and regulated by the Netherlands Authority for Financial Markets.

For all other jurisdiction-specific disclaimers please refer to https://www.clsa.com/disclaimer.html. The analysts/contributors to this report may be employed by any relevant CLSA entity or CLST, which is different from the entity that distributes the report in the respective jurisdictions.© 2022 CLSA and/or CL Securities Taiwan Co., Ltd. ("CLST").